12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Xu Y, Song R, Chen W, Strong K, Shrey D, Gedela S, Traynelis SF, Zhang G, Yuan H. Recurrent seizure-related GRIN1 variant: Molecular mechanism and targeted therapy. Annals of Clinical and Translational Neurology. PMID 34227748 DOI: 10.1002/acn3.51406  0.708
2020 Strong KL, Epplin MP, Ogden KK, Burger PB, Kaiser TM, Wilding TJ, Kusumoto H, Camp CR, Shaulsky G, Bhattacharya S, Perszyk RE, Menaldino DS, McDaniel MJ, Zhang J, Le P, et al. Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of -Methyl-d-aspartate Receptors. Acs Chemical Neuroscience. PMID 33326224 DOI: 10.1021/acschemneuro.0c00561  0.645
2020 Epplin M, Mohan A, Harris L, Zhu Z, Strong KL, Bacsa J, Le P, Menaldino DS, Traynelis SF, Liotta DC. The Discovery of Dihydropyrrolo[1,2-a]pyrazin-3(4H)-one-Based Second-Generation GluN2C- and GluN2D-Selective Positive Allosteric Modulators (PAMs) of the N-Methyl-D-Aspartate (NMDA) Receptor. Journal of Medicinal Chemistry. PMID 32538088 DOI: 10.1021/Acs.Jmedchem.9B01733  0.739
2017 Kaiser TM, Kell SA, Kusumoto H, Shaulsky G, Bhattacharya S, Epplin MP, Strong KL, Miller EJ, Cox BD, Menaldino DS, Liotta DC, Traynelis SF, Burger PB. The bioactive protein-ligand conformation of GluN2C-selective positive allosteric modulators bound to the NMDA receptor. Molecular Pharmacology. PMID 29242355 DOI: 10.1124/Mol.117.110940  0.823
2017 Strong KL, Epplin MP, Bacsa J, Butch CJ, Burger PB, Menaldino DS, Traynelis SF, Liotta DC. The Structure Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-ᴅ-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-ᴅ-Aspartate Receptors. Journal of Medicinal Chemistry. PMID 28586221 DOI: 10.1021/Acs.Jmedchem.7B00239  0.76
2017 Perszyk RE, Ogden KK, Strong KL, Liotta DC, Traynelis SF. Channel Open Probability Controls Allosteric Modulation of Potency and Efficacy Biophysical Journal. 112: 420a-421a. DOI: 10.1016/J.Bpj.2016.11.2249  0.717
2016 Swanger SA, Chen W, Wells G, Burger PB, Tankovic A, Bhattacharya S, Strong KL, Hu C, Kusumoto H, Zhang J, Adams DR, Millichap JJ, Petrovski S, Traynelis SF, Yuan H. Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains. American Journal of Human Genetics. PMID 27839871 DOI: 10.1016/J.Ajhg.2016.10.002  0.737
2016 Perszyk RE, DiRaddo JO, Strong KL, Low CM, Ogden KK, Khatri A, Vargish GA, Pelkey KA, Tricoire L, Liotta DC, Smith Y, McBain CJ, Traynelis SF. GluN2D-containing NMDA receptors mediate synaptic transmission in hippocampal interneurons and regulate interneuron activity. Molecular Pharmacology. PMID 27625038 DOI: 10.1124/Mol.116.105130  0.73
2014 Strong KL, Jing Y, Prosser AR, Traynelis SF, Liotta DC. NMDA receptor modulators: an updated patent review (2013-2014). Expert Opinion On Therapeutic Patents. 24: 1349-66. PMID 25351527 DOI: 10.1517/13543776.2014.972938  0.741
2014 Santangelo Freel RM, Ogden KK, Strong KL, Khatri A, Chepiga KM, Jensen HS, Traynelis SF, Liotta DC. Correction to Synthesis and Structure Activity Relationship of Tetrahydroisoquinoline-Based Potentiators of GluN2C and GluN2D Containing N-Methyl-d-aspartate Receptors. Journal of Medicinal Chemistry. 57: 4975. PMID 24878076 DOI: 10.1021/jm500710w  0.77
2013 Santangelo Freel RM, Ogden KK, Strong KL, Khatri A, Chepiga KM, Jensen HS, Traynelis SF, Liotta DC. Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors. Journal of Medicinal Chemistry. 56: 5351-81. PMID 23627311 DOI: 10.1021/Jm400177T  0.795
2012 Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC. Novel NMDA receptor modulators: an update. Expert Opinion On Therapeutic Patents. 22: 1337-52. PMID 23009122 DOI: 10.1517/13543776.2012.728587  0.711
Show low-probability matches.